Skip to Content

Copanlisib Pregnancy and Breastfeeding Warnings

Copanlisib is also known as: Aliqopa

Copanlisib Pregnancy Warnings

In animal studies, this drug caused embryo-fetal death (increased resorptions, increased post-implantation loss, and decreased numbers of fetuses/dams) and fetal abnormalities (gross external, soft tissue, and skeletal) at maternally-toxic doses as low as approximately 12% of the recommended dose for humans. Additionally, there were adverse findings in male and female animal reproductive systems including effects on the testes, epididymides, prostate, ovaries, uterus, and vagina. A dose-related reduction in the number of female animals in estrus also has been observed. There are no controlled data in human pregnancy or on human fertility. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

Safety has not been established during pregnancy; based on animal studies and its mechanism of action, this drug can cause fetal harm and is expected to cause adverse fertility effects. US FDA pregnancy category: Not Assigned Comments: -Following administration of radiolabeled drug to pregnant animals, approximately 1.5% of the radioactivity (parent compound and metabolites) reached the fetal compartment. -Advise pregnant women of the potential fetal risk, and conduct pregnancy testing prior to treatment initiation. -Counsel females of reproductive potential and males with female partners of reproductive potential to use highly effective contraception (failure rate of less than 1% per year) during treatment and for at least 1 month after the last dose.

See references

Copanlisib Breastfeeding Warnings

Breastfeeding is not recommended during treatment and for at least 1 month after the last dose. Excreted into human milk: Unknown Excreted into animal milk: Yes Comments: -The effects in the nursing infant and on milk production are unknown. -Following administration of radiolabeled drug to lactating animals, approximately 2% of the radioactivity was secreted into milk; the milk to plasma ratio of radioactivity was 25-fold.

See references

References for pregnancy information

  1. "Product Information. Aliqopa (copanlisib)." Bayer Pharmaceutical Inc, West Haven, CT.

References for breastfeeding information

  1. "Product Information. Aliqopa (copanlisib)." Bayer Pharmaceutical Inc, West Haven, CT.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.